Multiple Myeloma
📧 Sign up to get email alerts when something new happens for Multiple Myeloma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-03-24Clinical Trial Update: A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) [Phase 3]
A Phase 3 trial comparing mezigdomide, bortezomib and dexamethasone (MEZVd) versus pomalidomide, bortezomib and dexamethasone (PVd) in relap…
-
CLINICAL_TRIALS trial_result · 2026-03-24Clinical Trial Update: A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1) [Phase 1, Phase 2]
A Phase 1/2 clinical trial evaluating Enzomenib (DSP-5336) for acute leukemias, including acute myeloid leukemia and acute lymphoblastic leu…
-
CLINICAL_TRIALS research · 2026-03-24Clinical Trial Update: A Phase I Study of SHR-3836 in Patients With Multiple Myeloma [Phase 1]
A Phase I clinical trial of SHR-3836 for multiple myeloma is listed as not yet recruiting. The sponsor is Shanghai Hengrui Pharmaceutical Co…
-
CLINICAL_TRIALS trial_result · 2026-03-23Clinical Trial Update: Study of Belantamab Mafodotin as Pre- and Post-autologous Stem Cell Transplant and Maintenance for Multiple Myeloma [Phase 2]
Phase 2 study evaluating belantamab mafodotin as pre- and post-autologous stem cell transplant and maintenance therapy for multiple myeloma.
-
CLINICAL_TRIALS research · 2026-03-23Clinical Trial Update: Selinexor Maintenance Post CAR-T Cell Therapy for Multiple Myeloma [Phase 1]
A phase 1 clinical trial update evaluating selinexor as maintenance therapy after CAR-T cell therapy in multiple myeloma, currently recruiti…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2026-03-23Clinical Trial Update: A Study of Carfilzomib, Lenalidomide, Vorinostat, and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma [Phase 1, Phase 2]
Clinical trial update for a Phase 1/2 study of a four-drug combination (carfilzomib, lenalidomide, vorinostat, and dexamethasone) in relapse…
-
CLINICAL_TRIALS research · 2026-03-23Clinical Trial Update: A Study to Learn How Patients With Triple Class Refractory Multiple Myeloma (TCR-MM) Are Treated in Italian Centers for Blood Related Diseases
Pfizer-sponsored observational study in Italian hematology centers aims to understand how patients with triple class refractory multiple mye…
-
CLINICAL_TRIALS research · 2026-03-23Clinical Trial Update: Ohio State University Multiple Myeloma and Amyloidosis Data Registry and Sample Resource
This document announces an ongoing registry and sample resource at Ohio State University Comprehensive Cancer Center for plasma cell dyscras…
-
CLINICAL_TRIALS research · 2026-03-23Clinical Trial Update: Study of Selinexor With Carfilzomib, Isatuximab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma [Phase 1, Phase 2]
Phase 1/2 trial evaluating a combination of selinexor, carfilzomib, isatuximab, and dexamethasone in relapsed or refractory multiple myeloma…
-
CLINICAL_TRIALS other · 2026-03-23Clinical Trial Update: Halt Aging in Survivors of Blood Cancers: the HALTAging-1 Study [Phase 2]
Clinical trial HALTAging-1 is a Phase 2 study targeting aging in survivors of blood cancers; the trial is not yet recruiting.
-
CLINICAL_TRIALS trial_result · 2026-03-20Clinical Trial Update: Testing Crizotinib as Potentially Targeted Treatment in Cancers With MET Exon 14 Deletion Genetic Changes (MATCH - Subprotocol C2) [Phase 2]
Phase 2 MATCH subprotocol update assessing crizotinib for cancers with MET exon 14 deletions; results have been posted (2026-03-20).
-
CLINICAL_TRIALS trial_result · 2026-03-20Clinical Trial Update: A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple Myeloma [Phase 1, Phase 2]
Results from a Phase 1/2 study of CC-220 (iberdomide) as monotherapy and in combination for multiple myeloma, focusing on dose, safety, tole…
-
CLINICAL_TRIALS research · 2026-03-20Clinical Trial Update: An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial [Phase 3]
This entry details a Phase 3 extension study of Venetoclax for patients who completed prior Venetoclax trials. The study is currently active…
-
CLINICAL_TRIALS research · 2026-03-20Clinical Trial Update: Multiple Myeloma Extramedulary Disease Samples FFPE
BIWAKO-sponsored clinical trial evaluating extramedullary disease samples from multiple myeloma patients. The study is currently not yet rec…
-
CLINICAL_TRIALS research · 2026-03-20Clinical Trial Update: Identifying Effective and Cost-Conscious Maintenance Daratumumab Dosing [Phase 2]
This Phase 2 clinical trial update aims to identify an effective and cost-conscious maintenance dosing regimen for daratumumab in patients w…
-
CLINICAL_TRIALS research · 2026-03-20Clinical Trial Update: Impact of Budesonide on Incidence of ≥ Gr2 Diarrhea in Multiple Myeloma (MM) Patients Undergoing Autologous Stem Cell Transplant [Phase 2]
Phase 2 clinical trial evaluating whether budesonide reduces the incidence of grade 2 or higher diarrhea in multiple myeloma patients underg…
-
CLINICAL_TRIALS trial_result · 2026-03-19Clinical Trial Update: Testing Crizotinib as Potentially Targeted Treatment in Cancers With MET Genetic Changes (MATCH - Subprotocol C1) [Phase 2]
A Phase 2 MATCH subprotocol evaluating crizotinib for cancers with MET genetic alterations; results have been posted for this study.
-
CLINICAL_TRIALS trial_result · 2026-03-19Clinical Trial Update: A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma [Phase 1]
This Phase 1 study assesses the safety, pharmacokinetics, and preliminary activity of Cevostamab in participants with relapsed or refractory…
-
CLINICAL_TRIALS research · 2026-03-19Clinical Trial Update: A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment [Phase 1, Phase 2]
A Phase 1/2 trial to evaluate the safety, tolerability, and preliminary efficacy of Linvoseltamab in adults with recently diagnosed, treatme…
-
CLINICAL_TRIALS research · 2026-03-19Clinical Trial Update: Multiple Myeloma t(4 ;14) FFPE Samples
BIWAKO-sponsored clinical study investigating t(4;14) FFPE samples in multiple myeloma and malignant plasma cell neoplasms; the trial is cur…
-
CLINICAL_TRIALS trial_result · 2026-03-18Clinical Trial Update: ECT-001 (UM171) Expanded Cord Blood Transplant to Treat High-risk Multiple Myeloma [Phase 1, Phase 2]
A Phase 1/2 trial of ECT-001 (UM171) expanded cord blood transplant for high-risk multiple myeloma has completed.
-
CLINICAL_TRIALS research · 2026-03-18Clinical Trial Update: Study of Iopofosine I-131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) With Expansion in Waldenstrom [Phase 2]
Phase 2 clinical trial update for CLR-131 in select B-cell malignancies, with expansion into Waldenström macroglobulinemia. The study status…
-
CLINICAL_TRIALS research · 2026-03-18Clinical Trial Update: A Study of Ixazomib (NINLARO®) in Combination With Lenalidomide and Dexamethasone (IRD) for the Treatment of Participants With Multiple Myeloma (MM) [Phase 4]
Phase 4 clinical trial update evaluating ixazomib in combination with lenalidomide and dexamethasone for multiple myeloma. The study is acti…
-
CLINICAL_TRIALS research · 2026-03-18Clinical Trial Update: Study of Iberdomide, Bortezomib, Dexamethasone With Isatuximab Added on Demand for ND-NTE MM Patients [Phase 2]
A Phase 2 study evaluating the addition of on-demand isatuximab to Iberdomide, bortezomib, and dexamethasone in newly diagnosed, non-transpl…
-
CLINICAL_TRIALS research · 2026-03-18Clinical Trial Update: A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma [Phase 1]
A Phase 1 clinical trial update for BMS-986453 in relapsed or refractory multiple myeloma. Sponsor Juno Therapeutics (a Bristol-Myers Squibb…